Dec 2021: The following drugs are approved as of date for the treatment of liver cancer:. Please check the prescribing information before taking the drug.
Atezolizumab
Avastin (Bevacizumab)
Bevacizumab
Cabometyx (Cabozantinib-S-Malate)
Cabozantinib-S-Malate
Cyramza (Ramucirumab)
Infigratinib Phosphate
Keytruda (Pembrolizumab)
Lenvatinib Mesylate
Lenvima (Lenvatinib Mesylate)
Nexavar (Sorafenib Tosylate)
Nivolumab
Opdivo (Nivolumab)
Pemazyre (Pemigatinib)
Pembrolizumab
Pemigatinib
Ramucirumab
Regorafenib
Sorafenib Tosylate
Stivarga (Regorafenib)
Tecentriq (Atezolizumab)
Truseltiq (Infigratinib Phosphate)
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.
Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.
Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.
Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.
These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.
Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.
